preserved-heart-failure-treatment-FDA-US-approval
US FDA approves Jardiance® (empagliflozin) to treat adults with heart failure regardless of left ventricular ejection fraction
Vyhledat
emperor-preserved-chmp-positive-opinion
CHMP issues positive opinion to expand Jardiance (empagliflozin) indication based on unprecedented benefit in adult heart failure patients with preserved ejection fraction
EMPRISE-Study
EMPRISE-Study
preserved-heart-failure-treatment-approval-europe
preserved-heart-failure-treatment-approval-europe
reduced-heart-failure-treatment-approval-europe
European approval for treatment of adults with heart failure with reduced ejection fraction
Jardiance®
Treatment of adults with type 2 diabetes mellitus as an adjunct to diet and exercise.
Jardiance PI 07_2024
jardiance_pi_07_2023
jardiance_10_a_25_mg_spc_07_2023
jardiance_pi_06_2022
jardiance_10_a_25_mg_spc_07_2022_0
Jardiance PI 12_2023
SPC_Jardiance
Synjardy®
Treatment of type 2 diabetes mellitus to improve glycaemic control in adults when treatment with metformin does not lead to sufficient control or when patients are treated with jardiance® (empagliflozin) and metformin.
Boehringer-Ingelheim's-half-year-figures-2021
Press release on Boehringer Ingelheim's half-year figures 2021. Business development from January to June 2021.
empulse-trial-benefit-acute-heart-failure
Empagliflozin provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE Phase III trial
FDA- HFpEF-breakthrough-designation-EMPEROR-preserved
U.S. FDA issues Breakthrough Therapy Designation for the treatment of adults with heart failure with preserved ejection fraction
real-world-benefit-shown-in-T2D-treatment
Real-world evidence study shows type 2 diabetes treatment reduced risk of cardiovascular events and hospitalization for heart failure
emperor-preserved-heart-failure-full-data
Full results from EMPEROR-Preserved trial demonstrate significant improvement in heart failure outcomes in adults with preserved ejection fraction
emperor-preserved-kidney-subanalysis
New kidney sub-analysis of EMPEROR-Preserved trial demonstrates significant improvement in heart failure outcomes regardless of kidney disease status
Pro veřejnost
informace o léčivých přípravcích společnosti Boehringer Ingelheim registrovaných v České republice.
Pro odborníky
Informace o léčivých přípravcích společnosti Boehringer Ingelheim registrovaných v České republice